PAHC
Phibro Animal Health Corporation
NASDAQ: PAHC · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$36.32
-1.85% today
Updated 2026-06-05
Market cap
$1.25B
P/E ratio
13.21
P/S ratio
0.83x
EPS (TTM)
$2.33
Dividend yield
1.51%
52W range
$23 – $60
Volume
0.4M
WallStSmart proprietary scores
65
out of 100
Grade: B
Buy
Investment rating
7.3
Growth
B+6.0
Quality
B7.0
Profitability
B+4.7
Valuation
C3/9
Piotroski F-Score
Weak
2.1
Altman Z-Score
Grey zone
—
Industry rank
—
View all highly rated stocks (75+) →202 stocks currently score above 75
Price targets
Analyst target
$45.60
+25.55%
12-Month target
$71.25
+96.17%
Intrinsic (DCF)
$37.96
Margin of safety
-35.72%
1 Strong Buy0 Buy3 Hold0 Sell1 Strong Sell
Price chart
Stock snapshot
Strengths
+ ROE 26.32% — strong efficiency
+ Free cash flow $890000.00 — positive
+ Revenue growth 10.30% QoQ
Risks
- Piotroski 3/9 — weak financial health
- 35.72% above intrinsic value
- Debt/equity 2.18x — high leverage
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $942.26M | $977.89M | $1.02B | $1.30B | $1.50B |
| Net income | $49.17M | $32.61M | $2.42M | $48.26M | $24.02M |
| EPS | — | — | — | — | $2.33 |
| Free cash flow | $-5.39M | $-38.48M | $46.36M | $41.83M | $890000.00 |
| Profit margin | 5.22% | 3.33% | 0.24% | 3.72% | 6.35% |
Peer comparison
Smart narrative
Phibro Animal Health Corporation trades at $36.32. representing a P/E of 13.21x trailing earnings. Our Smart Value Score of 65/100 indicates the stock is good. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 2.09, it sits in the grey zone. TTM revenue stands at $1.50B. with profit margins at 6.35%. Our DCF model estimates intrinsic value at $37.96.
Frequently asked questions
What is Phibro Animal Health Corporation's stock price?
Phibro Animal Health Corporation (PAHC) trades at $36.32, on a P/E of 13.2x and a P/S of 0.8x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Phibro Animal Health Corporation overvalued?
Phibro Animal Health Corporation carries a Smart Value Score of 65/100 (Grade B), which we rate Buy. That score blends growth, quality, and valuation into one read. On valuation specifically, our conservative DCF puts intrinsic value at $37.96 against the $36.32 price, so on cash flow terms the market is paying a premium for Phibro Animal Health Corporation's growth. The Buy rating reflects that growth and quality, while the DCF flags that the price already assumes a lot.
What is the price target of Phibro Animal Health Corporation (PAHC)?
The 12-month analyst consensus target is $45.60, about 25.6% above the current $36.32. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is the intrinsic value of Phibro Animal Health Corporation (PAHC)?
Our DCF model estimates intrinsic value at $37.96, a -35.7% margin of safety versus today's $36.32. Intrinsic value is what the projected cash flows are worth today. A negative reading means the price is running ahead of that conservative estimate, leaving little downside cushion if growth slows.
What is Phibro Animal Health Corporation's revenue?
Phibro Animal Health Corporation's trailing twelve-month revenue is $1.50B. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Phibro Animal Health Corporation's Altman Z-Score is 2.09, which places it in the grey zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio0.83x
ROE26.32%
Beta0.61
50D MA$48.87
200D MA$43.53
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—